Breaking News

Evonik Appoints President for the Americas Region

Lacerda will succeed Guido Skudlarek, who recently became global Head of Evonik’s U.S.-based Health Care business.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Elias Lacerda of Evonik

Evonik, a global specialty chemicals company, has appointed Evonik executive Elias Lacerda President of the Americas region, effective February 1, 2026. Lacerda will succeed Guido Skudlarek, who recently became global Head of Evonik’s U.S.-based Health Care business line.

“The Americas region is crucial for Evonik’s success,” said Lauren Kjeldsen, Evonik’s Chief Operating Officer Custom Solutions and Management Board member responsible for the Americas. “I want to sincerely thank Guido for his successful work in growing the Americas business, and I look forward to Elias leading the next phase of our growth trajectory in North and South America. We see great potential there and have ambitious goals.”

“Elias is the perfect choice for the Americas region. Fluent in four languages and with an extensive global network, he combines scientific and business expertise in an ideal way,” said Kjeldsen.

A native Brazilian with degrees in chemical engineering and business administration (MBA), Lacerda has nearly three decades of experience with Evonik and its predecessors. He spent half of that time in Central and South America (CSA) managing businesses in the coatings sector and holding global leadership positions in Evonik’s Silica and Animal Nutrition business lines. Most recently, he served as head of the Coating Additives business line at the company’s headquarters in Essen, Germany. From 2018 to 2022, he led the CSA region as president. The CSA and North America regions were recently merged.

Evonik generates 30 percent of its annual revenue in the Americas and operates more than 30 production sites in the region, along with distribution centers and commercial offices. 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters